FDA Adapts Drug Development Tool Procedures to Adopt Alzheimer’s Simulation Tool

FDA recently featured an Alzheimer’s Disease clinical trial simulation tool as another positive, but low-visibility, step toward improving the drug development pathway for the disease. The process for accepting the tool may be as important as the tool itself.